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SECTION S1: STUDY INVESTIGATORS 
Belgium: Philip Van Damme. Canada: Angela Genge, Lorne Zinman. France: François 
Salachas. Germany: Albert Ludolph. United Kingdom: Chris McDermott. United States: 
Nazem Atassi, Robert Bucelli, Jonathan Glass, Ira Goodman, Jonathan Katz, Shafeeq Ladha, 
Nicholas Maragakis, Alan Pestronk, John Ravits, Randall Trudell. 
 
SECTION S2: EXPLORATORY OUTCOME DETAILS  
The Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R) is a 12-
question instrument for evaluation of the functional status of patients with ALS across four 
domains: respiratory function, bulbar function, gross motor skills, and fine motor skills. Each 
item is scored from 0 (no function) to 4 (full function), with a total possible score of 48 points.1  
Slow vital capacity (SVC) is a relatively less demanding (compared with forced vital 
capacity testing), noninvasive test of respiratory function frequently used in patients with ALS to 
monitor disease progression.2 The maximum of the percent predicted upright SVC value at each 
visit was used for the analysis. 
Handheld dynamometry (HHD) is a reliable and reproducible quantitative measure of 
muscle strength decline in ALS.3 For this analysis, 16 muscle groups (left and right shoulder 
flexion, left and right elbow flexion, left and right wrist extension, left and right abduction index 
finger, left and right abduction thumb, left and right abduction fifth digit, left and right knee 
extension, and left and right ankle dorsiflexion) were examined in both upper and lower 
extremities to derive the overall HHD megascore. 
Muscle strength values are normalized to Z-scores as (postbaseline measurements – 
mean)/SD and averaged to provide the HHD overall megascore. The mean and SD are based 
on the baseline values across all participants regardless of dose/treatment group. The 
megascore is created by averaging the eight bilateral measurement Z-scores, if no more than 
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10 of 16 muscle measures are missing. If >10 measures are missing, then the HHD megascore 
is considered as missing. 
 
SECTION S3: STATISTICAL ANALYSIS DETAILS  
The mixed model for repeated measures (MMRM) was used as the primary analysis method for 
inference. Summary statistics and least squares mean estimates with 95% CIs for the MMRM 
model were presented for changes from baseline in each of SOD1, ALSFRS-R, SVC, and 
neurofilament concentrations. Other imputation methods were also applied for sensitivity 
analysis purposes and analyzed using MMRM. The MMRM model included dose group, visit, 
treatment-by-visit interaction, baseline score, and baseline score by visit interaction terms, and 
adjusted for the covariate of disease progression type (fast-progressing [FP] vs. other). Only 
visits to Day 85 (and Day 92 for ALSFRS-R) were included in the model. An unstructured 
covariance matrix was used to model the within-participant variability. In case the model failed 
to converge, the Fisher scoring algorithm was used to provide initial values of the covariance 
parameters, instead of the default Newton-Raphson algorithm. In the event that none of these 
methods yielded convergence, the heterogeneous first-order autoregressive structure was used. 
For SOD1 and neurofilament concentrations, modeling was performed on a log scale due to the 
distribution of these data, and so the model for these outcomes was for the log ratio to baseline; 
geometric mean ratios and 95% CIs were presented.  
An MMRM was not used to analyze HHD megascore, due to the high level of missing 
data in such a small sample size and the collection of this outcome at fewer time points than 
other key outcomes (Days 22, 92, and 169). In particular, there is a high level of missing data in 
the placebo group as participants progressing in this group could not attend all clinic visits, in 
addition to the dropouts and death in this group. Furthermore, this assessment was only 
collected at Day 22 under a protocol amendment, by which time participants in Cohort 5 had 
already completed this visit, which reduces the amount of data collected for both the placebo 
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group and tofersen 20-mg group. Therefore, because the MMRM may result in unreliable results 
in a small, sparse dataset, the HHD megascore was consistently summarized using descriptive 
statistics for the overall population and by disease progression, using last observation carried 
forward for imputation of missing data to Day 92. 
The results for HHD and SVC are not presented for completers through to Day 169, as 
the data are sparse and have limitations in sample size. All participants receiving 100 mg 
tofersen completed all assessments for HHD and SVC; however, of the 12 placebo participants, 
only six and five completed all SVC and HHD assessments, respectively. A number of placebo 
participants either discontinued the study early or had disease progression, which resulted in an 
inability to attend clinic visits. ALSFRS-R was more complete, because this could be collected 
over the telephone. Excluding these participants leaves a small subset of completers in the 
placebo group for HHD and SVC, and comparing this group of participants with the active 
treatment group is misleading, as the true change in participants with disease progression is not 
reflected in the placebo group. 
 
SECTION S4: DEFINITION OF SOD1 FAST-PROGRESSING MUTATIONS 
Blinded to genetic results obtained from multiple ascending dose (MAD) participants, we 
conducted a literature review of SOD1 variants associated with ALS. We particularly focused on 
variants that had been reported as associated with an average disease course of <3 years from 
first symptom to death. We defined such variants as SOD1 fast-progressing mutations. 
Participants not meeting this fast-progressing definition were considered “other”. Ten SOD1 
variants fulfilled our criteria of (1) being described as fast-progressing mutations with sufficient 
detail in at least two independent cohorts (p.Ala5Val, p.Ala5Thr, p.Gly42Ser, p.His44Arg, 
p.Gly94Ala, p.Leu107Val, p.Leu39Val, p.Val149Gly), or (2) enriched and associated with a little 
variant rapid course of disease in a distinct ethnicity (p.Leu85Val, p.Arg116Gly). 
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Upon unblinding of the 100-mg subgroup, an ALSFRS-R slope of 0.0 (at baseline and 
Day 85) in a participant carrying the SOD1 mutation p.Arg116Gly triggered a revision to the fast 
progressor definition to include a criterion for a prerandomization ALSFRS-R of ≥0.2 points per 
month in an effort to ensure the participants were in fact progressing at the time of enrollment. 
Forty-seven MAD participants had SOD1 gene variants that could be assigned to 
previously described mutations, one participant had a novel SOD1 mutation, and two had 
variants that could not be assigned to known SOD1 alleles. In total, 22 SOD1 mutations were 
identified; of those, the fast-progressing mutation p.Ala5Val was most prevalent (N = 10). 
 
SECTION S5: PHARMACOKINETICS 
Measured plasma concentrations peaked between 2 and 6 hours after intrathecal bolus 
administration and were dose proportional (Supplemental Fig. S4A). Trough CSF 
concentrations were less than dose proportional and were highest in the 100-mg group, lowest 
in the 20-mg group, and similar in the 40- and 60-mg groups (Supplemental Fig. S4B). 
Examination of trough CSF concentrations from baseline to Day 169 suggested that steady-
state concentrations were achieved following the third loading dose on Day 29. Repeat 
pharmacokinetic assessments during the study demonstrated marginal or no apparent 
accumulation after the third loading dose in the plasma or in the CSF. There was moderate to 
high inter- and intraparticipant variability in CSF concentration profiles (most coefficients of 
variation were ≥50%). 
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SECTION S6: SUPPLEMENTARY FIGURES 
 
Figure S1. MAD Study Design. 
*Single ascending dose study was performed first. †Exploratory outcomes shown were 
analyzed in this study. Additional exploratory outcomes include changes from baseline (BL) in 
electrical impedance myography, motor unit number index, ALS Assessment Questionnaire 
scores, Fatigue Severity Scale scores, EuroQol Five-Dimension Three-Level Questionnaire 
scores, 36-Item Short Form Health Survey, and Zarit Burden Interview scores, and possible 
relationships between tofersen pharmacokinetics, CSF SOD1 protein concentrations, and 
potential biomarker measures including misfolded or mutant SOD1, phosphorylated 
neurofilament heavy chains (pNfH), and neurofilament light chains (NfL). Analyses of these 
exploratory outcomes are ongoing. Two participants in MAD received an initial dose in the 
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Figure S2. CONSORT Flow Diagram. 
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Figure S3. CSF Laboratory Values. 
Panel A, leukocytes. Panel B, protein. Erythrocyte results >10,000 are excluded. 
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Figure S4. Tofersen Exposure. 
Panel A shows the geometric mean (standard error [SE]) concentration of tofersen in plasma, according to dose group, over the 24-hour 
periods after the administration of the first dose (Day 1) and fifth dose (Day 85). Panel B shows the maximum predose (i.e., 28-day trough) 
geometric mean (SE) concentration of tofersen in CSF according to dose group. Tofersen values below limit of quantitation are set to half of 
lower limit of quantitation (1 ng/mL) in calculations. *N = 9 for Day 1: 6 hours postdose, 20 mg. †N = 9 for Day 85: predose, 40 mg. ‡Final 
dosing day. 
  




Figure S5. CSF SOD1 in Observed Completers to Day 169. 
Values below the lower limit of quantitation (15.6 ng/mL) and data points where N = 1 are not presented. Completers are defined as 
participants who completed the study through to Day 169 (i.e., all expected visits).  
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Figure S6. Change from Baseline in ALSFRS-R Score for All Cohorts. 
Postbaseline missing values were imputed using an MMRM model. Means were calculated using the least squares method. 
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Figure S7. Change from Baseline in Percent Predicted SVC for All Cohorts. 
Postbaseline missing values were imputed using an MMRM model. Means were calculated using the least squares method.  
Page 15 of 31 
 
 
Figure S8. Change from Baseline in HHD Megascore for All Cohorts. 
Postbaseline missing values were imputed using last observation carried forward. Due to the timing of the protocol amendment to collect HHD 
at Day 22, no participants in Cohort 5 (placebo and 20 mg) have data for HHD at this visit. 
  




Figure S9. Total ALSFRS-R Score in Observed Completers to Day 169. 
Completers are defined as participants who completed the study through to Day 169 (i.e., all expected visits). Some assessments were not 
performed at certain visits for participants in Cohort 5 based on the timing of protocol amendment affecting both those on placebo and 20 mg in 
this cohort. *N = 7 for Day 92. †Due to the timing of the protocol amendment to collect ALSFRS-R at Day 92, no participants were included for 
analysis on Day 92 for this cohort. 
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Figure S10. Baseline Neurofilament Concentrations Were Associated with Disease Activity as Measured by Prerandomization 
ALSFRS-R Slope. 
pNfH in plasma (Panel A) and CSF (Panel B); NfL in plasma (Panel C) and CSF (Panel D). 
  




Figure S11. Baseline Neurofilament Concentrations Were Highest in Fast-Progressing Participants. 
pNfH in plasma (Panel A) and CSF (Panel B); pNfL in plasma (Panel C) and CSF (Panel D).
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Figure S12. Effect of Tofersen on Plasma and CSF Neurofilament Concentrations. 
Panel A shows geometric mean (95% CI) ratios to baseline for plasma and CSF pNfH and NfL for overall, fast-progressing, and other 
participants. Postbaseline missing values were imputed using an MMRM model. Panel B shows individual neurofilament traces for fast-
progressing participants. Geometric mean ratios were calculated using the least squares method. 
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Figure S13. Ratio to Baseline Plasma pNfH (Panel A) and NfL (Panel B) Concentration in Observed Completers to Day 169. 
Completers are defined as participants who completed the study through to Day 169 (i.e., all expected visits). *N = 4 at Day 106. †Due to the 
timing of the protocol amendment to collect plasma samples for biomarkers at Day 106, no participant in the placebo and 20-mg dose group 
had data for plasma pNfH and NfL at this visit. 
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Figure S14. Ratio to Baseline CSF pNfH (Panel A) and NfL (Panel B) Concentration in Observed Completers to Day 169. 
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SECTION S7: SUPPLEMENTARY TABLES 
Table S1. SOD1 Mutations Associated with Fast-Progressing ALS, Reported as Showing an Average Time from First Symptom to 















Rate – Mean (SD) Country Reference 
p.Ala5Val A4V 33032096 rs121912442 c.14C>T Missense Fast 
87 
yr: 1.4 (0.9); median, 1.0; range: 
0.5–4.0 
USA Cudkowicz et al, 19974 
63 yr: 1.4 (0.7); median, 1.2 USA Bali et al, 20175 
4 yr: 0.9 
Sweden/ 
Finland 
Andersen et al, 19976 
75 yr: 1.0 (0.4) USA Juneja et al, 19977 
p.Ala5Thr A4T 33032095 rs121912444 c.13G>A Missense Fast 
7 yr: 1.5 (0.4) USA Juneja et al, 19977 
2 yr: 0.8 (0.05) USA Bali et al, 20175 
p.Gly42Ser G41S 33036154 rs121912433 c.124G>A Missense Fast 
8 mo: 11.6 (1.7); range, 9–13 Italy Rainero et al, 19948 
4 mo: range, <12–15 Italy Battistini et al, 20059 
8 yr: 0.9 (0.3); range, 2–15 Italy Battistini et al, 201010 
4 yr: 0.9 (0.5); median, 1.0 USA Cudkowicz et al, 19974 
1 yr: 0.4 USA Bali et al, 20175 
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p.His44Arg H43R 33036161 rs121912435 c.131A>G Missense Fast 
4 yr: 2.8 (1.5); median, 2.5 USA Cudkowicz et al, 19974 
7 yr: 1.4 (0.8) USA Juneja et al, 19977 
1 yr: 0.3 USA Bali et al, 20175 
p.Leu85Val L84V 33039584 rs121912452 c.253T>G Missense Fast 5 yr: 1.6 (0.5) Japan Abe et al, 199611 
p.Gly94Ala G93A 33039612 – c.281G>C Missense Fast 
9 yr: 2.2 (1.5); median, 1.7 USA Cudkowicz et al, 19974 
2 yr: 2.2 (0.6) USA Bali et al, 20175 
6 yr: 2.4 (1.4) USA Juneja et al, 19977 
p.Arg116Gly R115G 33039677 – c.346C>G Missense Fast 8 yr: mean, 2–3 Germany Rabe et al, 201012 
p.Leu107Val L106V 33039650 rs121912440 c.319C>G Missense Fast 
2 yr: 1.2 (0.1) USA Juneja et al, 19977 
4 yr: 2.3 (1.3); median, 1.9 USA Cudkowicz et al, 19974 
p.Leu39Val L38V 33036145 rs121912432 c.115C>G Missense Fast 12 
yr: 2.8 (1.9); median, 2.0; range, 
0.9–7.0 
USA Cudkowicz et al, 19974 
p.Val149Gly V148G 33040872 – c.446T>G Missense Fast 
7 yr: 2.0 (0.9) USA Juneja et al, 19977 
4 yr: 2.3 (2.2); median, 1.3 USA Cudkowicz et al, 19974 
2 yr: mean, 2.5 Germany Rabe et al, 201012 
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Table S2. Demography and Baseline Characteristics. 
  Tofersen 
 
Placebo* 
(N = 12) 
20 mg 
(N = 10) 
40 mg 
(N = 9) 
60 mg 
(N = 9) 
100 mg 
(N = 10) 
Mean (SD) age — yr 49.2 (11.0) 41.5 (10.7) 58.0 (11.1) 45.6 (10.7) 48.9 (10.8) 
Male — n (%) 7 (58.3) 7 (70.0) 4 (44.4) 6 (66.7) 4 (40.0) 
Riluzole use — n (%) 5 (41.7) 8 (80.0) 5 (55.6) 8 (88.9) 7 (70.0) 
Mean (SD) time since symptom onset — 
mo 
49.4 (49.0) 61.4 (44.1) 64.2 (58.3) 72.3 (83.4) 41.4 (41.4) 
Mean (SD) baseline ALSFRS-R score 36.0 (4.8) 34.4 (7.4) 36.7 (6.9) 38.3 (6.5) 38.2 (2.4) 
Mean (SD) prerandomization ALSFRS-R 
slope — score change/month 
–0.65 (0.60) –0.41 (0.37) –0.27 (0.20) –0.34 (0.42) –0.61 (0.59) 
Mean (SD) baseline % predicted SVC 77.4 (21.8) 79.8 (17.7) 88.3 (15.6)† 72.8 (17.3) 85.5 (10.3) 
Mean (SD) baseline HHD megascore 0.02 (1.06) –0.11 (0.36) 0.09 (1.16) 0.08 (0.67) –0.05 (0.67) 
Geometric mean (SE) baseline CSF 











SOD1 mutation, n (%) 12 (100.0) 10 (100.0) 9 (100.0) 9 (100.0) 10 (100.0) 
A4V‡ 4 (33.3) 1 (10.0) 1 (11.1) 2 (22.2) 2 (20.0) 
D90A 0 1 (10.0) 2 (22.2) 0 0 
I113T 0 1 (10.0) 1 (11.1) 1 (11.1) 2 (20.0) 
L106V‡ 0 0 0 0 1 (10.0) 
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R115G‡ 0 0 0 0 1 (10.0) 
Unknown 0 1 (10.0) 0 0 0 
Other 8 (66.7) 6 (60.0) 5 (55.6) 6 (66.7) 4 (40.0) 
 
*Combined placebo from all cohorts. 
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(N = 10) 
40 mg 
(N = 9) 
60 mg 
(N = 9) 
100 mg 
(N = 10) 
Mean difference: Ratio to baseline in 
CSF SOD1 (95% CI) percentage points 
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